You are here

WALL STREET INSIGHT

US sectoral stocks taking turns on vaccine headlines

BT_20201123_RCCOL23_4337320.jpg
Moderna was the second major vaccine maker to report a spectacularly high rate of responsiveness in clinical-trial participants.

THE US stock market is tracking a race against the clock as stimulus negotiators, vaccine makers and transition officials attempt to save the US and its economy from a second wave of Covid-19 before it is too late.

The holiday season, which begins this week with the celebration of...

BT is now on Telegram!

For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes